Claims:

1. A compound which is 1-acetyl-4-((5-chloropyrimidin-2-yl)amino)-2-methyl-1,2,3,4-tetrahydroquinoline-6-carboxamide or a salt thereof.

2. A compound of formula (XIVa) according to claim 1 which is (2*S*,4*R*)-1-acetyl-4-((5-chloropyrimidin-2-yl)amino)-2-methyl-1,2,3,4-tetrahydroquinoline-6-carboxamide



(XIVa)

or a salt thereof.

3. A compound according to any one of claims 1 - 2, or a pharmaceutically acceptable salt thereof.

4. A compound according to any one of claims 1 – 2 in the form of a free base.

5. A pharmaceutical composition which comprises a compound or a pharmaceutically acceptable salt thereof as defined in claim 3 and one or more pharmaceutically acceptable carriers, diluents or excipients.

6. A combination product comprising a compound or a pharmaceutically acceptable salt thereof as defined in claim 3 together with one or more other therapeutically active agents.

7. A compound or a pharmaceutically acceptable salt thereof as defined in claim 3 for use in therapy.

8. A compound or a pharmaceutically acceptable salt thereof as defined in claim 3, for use in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated, wherein the disease or condition is an acute or chronic autoimmune and/or inflammatory condition or wherein the disease or condition involves an inflammatory response to an infection with bacteria, a virus, fungi, a parasite or their toxins or wherein the disease or condition is a viral infection or wherein the disease or condition is cancer.

9. The use of a compound or a pharmaceutically acceptable salt thereof as defined in claim 3, in the manufacture of a medicament for the treatment of diseases or conditions for which a bromodomain inhibitor is indicated in a human subject in need thereof, wherein the disease or condition is an acute or chronic autoimmune and/or inflammatory condition or wherein the disease or condition is cancer.